3 results match your criteria: "Yale-New Haven Cancer Center[Affiliation]"
Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors.
Am J Clin Oncol
April 2023
Department of Medical Oncology, Brown University/Alpert School of Medicine, Providence, RI.
Purpose: VNP40101M is a new alkylating agent that demonstrated broad anti-tumor activity in murine tumor models. A phase I trial was initiated to determine the toxicities, maximum tolerated dose, and pharmacokinetics of VNP40101M by short IV infusion.
Study Design: The starting dose was 3 mg/m(2) every four weeks, and was escalated in successive cohorts as follows: 6, 12, 24, 40, 60, 80, and 100 mg/m(2).
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Clin Cancer Res
September 2003
Yale-New Haven Cancer Center, New Haven, Connecticut 06520, USA.
Article Synopsis
- A Phase I study was conducted to evaluate the safety, pharmacokinetics, and maximum tolerated dose of Triapine, a ribonucleotide reductase inhibitor, in patients with advanced cancer.
- Triapine was given through a daily 2-hour infusion for 5 days, with dose adjustments made due to adverse events and a modified escalation scheme implemented.
- The trial involved 32 patients, revealing that the primary toxic effects included grade 3-4 leukopenia and various grade 1-2 nonhematological side effects, with significant hematological toxicity observed at higher doses.